PMID- 36583981
OWN - NLM
STAT- MEDLINE
DCOM- 20230106
LR  - 20230404
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 24
IP  - 2
DP  - 2023 Feb 1
TI  - Effects of glucagon-like peptide-1 receptor agonists on patients with heart 
      failure: a meta-analysis of randomized controlled trials.
PG  - 132-137
LID - 10.2459/JCM.0000000000001430 [doi]
AB  - AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of 
      major adverse cardiovascular events (MACE) and heart failure in patients with 
      type 2 diabetes mellitus (T2DM). However, these outcomes are not similarly 
      demonstrated in those with prior heart failure in subgroup analyses of several 
      randomized controlled trials (RCTs). We evaluated the effect of GLP-1RAs on MACE 
      and heart failure admissions for T2DM patients with a previous history of heart 
      failure. METHODS: We searched PubMed and EMBASE through March 2022 to identify 
      RCTs examining the effects of GLP-1RAs compared with placebo on MACE and heart 
      failure admission in T2DM patients with a history of heart failure. MACE were 
      mainly defined as a composite of cardiovascular death, nonfatal myocardial 
      infarction, and nonfatal stroke. We performed a meta-analysis with a 
      random-effects model. RESULTS: Our analysis included subgroup analyses of 7 RCTs 
      enrolling a total of 8,965 patients with T2DM and heart failure. Pooled analysis 
      demonstrated a significantly decreased MACE (hazard ratio, 0.88; 95% confidence 
      interval, 0.78-0.99; P = 0.039; I2 = 18.1%) in the GLP-1RAs group. In contrast, 
      the rate of heart failure admission was not significantly different between the 
      two groups (hazard ratio, 1.03; 95% confidence interval, 0.91-1.16; P = 0.67; 
      I2 = 0.0%). CONCLUSION: GLP-1RAs significantly reduced MACE in T2DM patients with 
      prior heart failure compared with the placebo group but did not affect the risk 
      of heart failure admission.
CI  - Copyright (c) 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.
FAU - Obata, Shota
AU  - Obata S
AD  - Department of Medicine, Mount Sinai Beth Israel, New York, New York, USA.
FAU - Miyamoto, Yoshihisa
AU  - Miyamoto Y
AD  - Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan.
FAU - Slipczuk, Leandro
AU  - Slipczuk L
AD  - Division of Cardiology, Montefiore Medical Center, Bronx, New York, USA.
FAU - Takagi, Hisato
AU  - Takagi H
AD  - Department of Cardiothoracic Surgery, Shizuoka Medical Center, Shizuoka, Japan.
FAU - Kuno, Toshiki
AU  - Kuno T
AD  - Division of Cardiology, Montefiore Medical Center, Bronx, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptide-1 Receptor/agonists/therapeutic use
MH  - *Heart Failure/epidemiology
MH  - Randomized Controlled Trials as Topic
EDAT- 2022/12/31 06:00
MHDA- 2023/01/04 06:00
CRDT- 2022/12/30 13:03
PHST- 2022/12/30 13:03 [entrez]
PHST- 2022/12/31 06:00 [pubmed]
PHST- 2023/01/04 06:00 [medline]
AID - 01244665-202302000-00007 [pii]
AID - 10.2459/JCM.0000000000001430 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2023 Feb 1;24(2):132-137. doi: 
      10.2459/JCM.0000000000001430.